Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence features.

Proc Natl Acad Sci U S A · 2024 · PMC10823214 · PMID 38241441

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

For each trial and reference sequence, we found a substantial and highly significant decline in PE of both VRC01 dose groups pooled with an increasing epitope distance.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.